Spotlight on… Comorbid substance use and mental health problems
The co-occurrence of substance use disorders with other mental health conditions (dual disorders) is very common, and these patients typically have more severe problems – clinically and psychosocially – than patients with only substance use disorders. This spotlight outlines key issues related to...
Spotlight on… Understanding and using evidence
The various types of evidence that may be used in responding to drug problems differ in their strengths and weaknesses and in the information they can provide. Drug-related problems are multifaceted and require not only medical, but also socioeconomic and educational interventions. As a result, it...
Spotlight on… Health and social responses to drug problems during the Covid-19 pandemic
On 11 March 2020, the World Health Organization declared COVID-19 a pandemic. Since then, the virus has claimed millions of lives and has transformed nearly every aspect of individual and collective reality. This spotlight outlines the main impacts of COVID 19 pandemic on drug availability and use...
Action framework for developing and implementing health and social responses to drug problems
This action framework was developed to help clarify current thinking about the response process and the factors to consider at each stage of it. It will be of particular interest to those planning health and social policy or interventions to address drug problems, but can equally apply to responses...
Health and social responses to drug problems: A European guide
The Health and social responses to drug problems: a European guide 2021 was developed to support practitioners and policymakers in tackling the negative consequences of drug use. The guide is composed of four sets of miniguides that look at responses to a range of drug problems in Europe. Framing...
Ad hoc publication
Methamphetamine from Afghanistan: signals indicate that Europe should be better prepared
This report examines the relatively recent emergence of methamphetamine production in Afghanistan and identifies actions that may be taken in Europe to mitigate the risks. The publication stresses the importance of increasing awareness on the issue among policymakers in Europe as well as among law-...
Implementing quality standards for drug services and systems: a six-step guide to support quality assurance
This publication provides a practical introduction to the area of quality standards and quality assurance mechanisms and the key steps involved in their implementation in drug services and systems. The primary audience for this guide is those responsible for commissioning, planning or providing...
Synthetic cannabinoids in Europe – a review
This report provides a technical review of the current body of knowledge regarding synthetic cannabinoids that are monitored by the the EU Early Warning System. The aim of this report is to strengthen situational awareness of synthetic cannabinoids in Europe and to help stakeholders prepare for,...
Manuals and guidelines
EMCDDA guide to holding a stakeholder round-table on supporting hepatitis C testing and care in drug services
This guide is aimed at supporting teams organising stakeholder round-table meetings as part of their regional or national diagnostic processes aimed at identifying barriers to and opportunities to increase hepatitis C virus testing and care in drug services.
Manual: increasing access to hepatitis C testing and care for people who inject drugs
This manual provides a step-by-step guide for those involved in planning and managing infectious diseases and drug services, focusing on how to identify barriers to and opportunities for improving provision of HCV testing and access to treatment for people who use drugs. In particular, it focuses...
Increase access to HCV testing and care in drugs services — a toolkit
This EMCDDA's hepatitis C toolkit aims to support countries in reaching the elimination goal by increasing access of people who inject drugs to testing and care through drugs services. It brings together a range of practical resources including guides, checklists, questionnaires and useful...
Elimination barometer on viral hepatitis among people who inject drugs in Europe
The elimination barometer for hepatitis B and C among people who inject drugs is designed to support countries affiliated to the EMCDDA in monitoring their progress towards the Sustainable Development Goal 3.3 and the elimination of viral hepatitis as a major public health threat by 2030. Under...
Final EMCDDA annual accounts for the financial year 2020
These accounts have been drawn up and signed off by the Accounting Officer on 31 May 2021 and approved by the Director on 1 June 2021. The opinion of the Management Board was given favourably on 24 June 2021. The present annual accounts, together with the opinion of the Management Board, have been...
Prison and drugs in Europe: current and future challenges
This publication provides an overview of current knowledge and the latest developments in the field of drug use and prison in Europe. The report explores in depth the epidemiology of drug use and drug-related problems among the prison population, the available social and health service responses to...
Ad hoc publication
EMCDDA trendspotter briefing Illicit drug markets and supply in the Western Balkans: Impact of COVID-19
The Western Balkans (Albania, Bosnia and Herzegovina, Kosovo*, Montenegro, North Macedonia and Serbia) registered the main waves of COVID-19 infections later than most of the EU countries, but containment strategies were implemented at the same time and with equal force as in the rest of Europe....
General report of activities
General Report of Activities 2020 – key achievements and governance: a year in review
The General Report of Activities is an annual publication providing a detailed progress report of the EMCDDA’s activities over a 12-month period. It catalogues the Centre’s achievements in each area of its annual work programme. The report is a useful information source for all those seeking...
New benzodiazepines in Europe – a review
This report provides a technical review of the current body of knowledge regarding new benzodiazepines that are monitored by the EU Early Warning System. The aims of this report are to strengthen situational awareness of new benzodiazepines in Europe, and to help stakeholders prepare for and...
European Drug Report
European Drug Report 2021: Trends and Developments
The Trends and Developments report presents the EMCDDA’s latest analysis of the drug situation in Europe. Focusing on illicit drug use, related harms and drug supply, the report contains a comprehensive set of national data across these themes and key harm reduction interventions.
Perspectives on Drugs (PODs)
Wastewater analysis and drugs — a European multi-city study (Perspectives on drugs)
The findings of the largest European project to date in the emerging science of wastewater analysis are taken up in this ‘Perspective on drugs’. The project in question analysed wastewater in 82 European cities and towns to explore the drug-taking habits of those who live in them. The results...